TBIO.jpg
Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
06 mai 2021 16h13 HE | Translate Bio, Inc.
-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year...
TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05 mai 2021 16h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit
28 avr. 2021 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
20 avr. 2021 16h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Key Leadership Additions and Promotions
19 avr. 2021 07h30 HE | Translate Bio, Inc.
-- Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringingstrategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary...
TBIO.jpg
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
19 avr. 2021 07h30 HE | Translate Bio, Inc.
-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy...
TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07 avr. 2021 16h05 HE | Translate Bio, Inc.
LEXINGTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
23 mars 2021 16h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Appoints Dr. Rand Sutherland as President
22 mars 2021 07h30 HE | Translate Bio, Inc.
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 ...
TBIO.jpg
Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)
17 mars 2021 16h05 HE | Translate Bio, Inc.
-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports...